Genomic Testing Cooperative

12/23/2025

Use GTC's Solid Tumor Profile Plus to distinguish and classify melanocytic lesions and skin sarcomas. Get the same comprehensive biomarker analysis you do with FFPE tissues.

Learn more:https://genomictestingcooperative.com/genomic-tests/solid-tumor-profile-plus/

12/22/2025

At theASH Annual Meeting, our collaborators presented pioneering AML research leveraging AI and integrated molecular data to improve prognostication and treatment personalization. Highlights include:

AI-Driven Prediction of Ven-HMA Response and Relapse
Outcomes in Elderly African Ancestry AML
Real-World Validation of Prognostic Molecular Risk Signature
AI-Based Transcriptomic Signature for IDH1/2 AML

Learn more: https://genomictestingcooperative.com/67th-ash-annual-meeting-posters/

12/19/2025

Every week, GTC shares the latest on our innovations, product updates, publications, and events. Don’t miss out on what’s shaping the future of cancer testing.

Sign up for our newsletter today: https://genomictestingcooperative.com/newsletter/

12/18/2025

https://genomictestingcooperative.com/67th-ash-annual-meeting-posters

12/17/2025

https://www.youtube.com/watch?v=RVQRTSSEIWA

Dr. Albitar provides an overview GTC's cutaneous testing.

Learn more:https://genomictestingcooperative.com/genomic-tests/solid-tumor-profile-plus/

Enjoy the videos and music you love, upload original content, and share it all with friends, family, and the world on YouTube.

12/16/2025

MGMT methylation analysis can be added to any CSF specimen when tumor DNA is detected. A new checkbox has been added to our requisition form to make this easy.

Order now: https://genomictestingcooperative.com/client-services/

12/15/2025

GTC offers an expanded suite of IHC markers as an add on to any of our solid tumor tissue tests. These CDx assays help refine patient selection for targeted therapies and strengthen clinical decision-making with clearer, more actionable insights.

Learn more: https://genomictestingcooperative.com/ihc-testing/

12/15/2025

We wish our friends who celebrate Hannukah a joyful first night. May your dreidel land on gimel and your latkes be tasty.

12/12/2025

GTC is pleased to announce the addition of MET Immunohistochemistry (IHC) to our comprehensive solid tumor testing portfolio.

MET IHC can identify patients with non-small cell lung cancer (NSCLC) who may be eligible for the targeted therapy telisotuzumab vedotin-tllv (EMRELIS™).

Learn more:https://genomictestingcooperative.com/ihc-testing/

12/11/2025

NCCN now recommends considering DPYD genotyping before initiating fluoropyrimidine-based chemotherapy (e.g., 5-FU or capecitabine) in certain GI cancers.

At GTC, our Solid Tumor Profile Plus and Liquid Trace includes evaluation of the DPYD gene polymorphism linked to fluoropyrimidine toxicity.

Learn more: https://genomictestingcooperative.com/genomic-tests/solid-tumor-profile-plus/

12/10/2025

All our ASH presentations now available on the GTC website

https://genomictestingcooperative.com/67th-ash-annual-meeting-posters

12/09/2025

Using GTC's Solid Tumor Profile Plus and Liquid Trace - Solid Tumor on CSF will provide comprehensive analysis and help resolve diagnostic dilemmas on brain tumors.

Learn more;https://genomictestingcooperative.com/genomic-tests/